News from Heart Failure 2025: SOGALDI-PEF trial results

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
ESC Heart Failure 2025
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
- João Pedro Ferreira, MD, PhD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Effects of dapaglifozin on QoL and functional status in elderly TAVI patients with aortic stenosis
Effects of dapaglifozin on QoL and functional status in elderly TAVI patients with aortic stenosis
ESC Heart Failure 2025
Effects of dapaglifozin on QoL and functional status in elderly TAVI patients with aortic stenosis
- Clara Bonanad Lozano, MD, PhD
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
ESC Heart Failure 2025
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
- Varun Sundaram, MD, PhD

Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF